Mr. Hugh MacNaught reports

VENTRIPOINT ANNOUNCES CLOSING OF SECOND AND FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT PURSUANT TO LISTED ISSUER FINANCING EXEMPTION

Ventripoint Diagnostics Ltd. has closed the second and final tranche of its non-brokered private placement offering, as described in its news releases of Aug. 28, 2024, Aug. 29, 2024, Sept. 17, 2024, Oct. 15, 2024, and Oct. 18, 2024, pursuant to the listed issuer financing exemption (LIFE) under Part 5A of National Instrument 45-105, Prospectus Exemptions, resulting in the issuance of 494,041 units of the company at a price of 19.5 cents per unit for aggregate gross proceeds of $96,338.

In total, Ventripoint issued an aggregate of 2,845,771 units pursuant to the LIFE offering for aggregate gross proceeds of $554,925. Each unit issued pursuant to the LIFE offering consists of one common share of the corporation and one share purchase warrant. Each warrant entitles the holder to purchase one common share of the corporation at an exercise price of 30 cents for a period of six months from the date of issuance. The common shares and warrants issued pursuant to the LIFE offering are not subject to a hold period.

Completion of the LIFE offering is subject to the satisfaction of customary closing conditions, including the approval of TSX Venture Exchange.

The corporation will use the proceeds of the offering to finance operational costs related sales and marketing, for additional key personnel, and for general working capital purposes.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.